QuantumPharm IPO oversubscribed ‘by 10 times’ as retail investors pile in to Hong Kong’s first pre-revenue tech regime listing
Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.
Retail investors have rushed to subscribe to Tencent-backed AI drug researcher QuantumPharm on the first day of its HK$1.13 billion (US$144.5 million) IPO, encouraged by recent market rallies and listing reforms.